Owkin<\/a>.<\/p>\nAgentic AI company Owkin and Sanofi have extended their collaboration with a five-year license for K Pro, Owkin\u2019s AI scientist, under which Owkin will lead the end-to-end development of novel, purpose-built biopharma agents for Sanofi. Owkin pitches K Pro as a system that reasons over biological data and orchestrates AI agents to run research and decision-making tasks that traditionally fall to teams of human scientists.<\/p>\n
K Pro pairs Owkin\u2019s multimodal patient-data network with specialized agentic AI to support each stage of drug development, from early discovery through clinical trials, alongside competitive intelligence. The new agents, which Owkin describes as autonomous assistants capable of running complex R&D tasks, will be deployed through the platform with the stated goal of complementing and reinforcing Sanofi\u2019s existing agentic capabilities.<\/p>\n
The extension \u201cmarks a shift toward truly embedded AI,\u201d said Thomas Clozel, Owkin\u2019s CEO and co-founder, in a statement. Embedded has a concrete meaning in Owkin\u2019s architecture. K Pro is an orchestrator whose individual tools and agents sit behind MCP servers, the same modular layer Owkin used to ship its first external agent, Pathology Explorer, through Anthropic\u2019s Claude earlier this year. The Sanofi agents would run on that interoperable plumbing inside Sanofi\u2019s own stack, rather than as analyses Owkin delivers from the outside.<\/p>\n
Emmanuel Frenehard, Sanofi\u2019s chief digital officer, framed the agents as part of a broader frontier-AI push. \u201cBy implementing purpose-built agentic systems into our workflows, we aim to empower our teams to operate with greater speed, depth, and confidence,\u201d he said. It is a bet Sanofi is not placing on Owkin alone: in January, the company expanded a parallel collaboration with CytoReason, another agentic-AI vendor, in a deal valued at up to $16 million.<\/p>\n
The collaboration between Sanofi and Owkin dates back to November 2021, when Sanofi made a $180 million equity investment in Owkin alongside a $90 million, three-year oncology collaboration spanning four cancers: non-small cell lung cancer, triple-negative breast cancer, mesothelioma, and multiple myeloma. The initial scope covered target identification in oncology and patient subgrouping, and later expanded to drug positioning for Sanofi\u2019s immunology pipeline. Sanofi\u2019s role has since evolved from investor and customer to a partner running Owkin\u2019s agents inside its own workflows.<\/p>\n
Jonas B\u00e9al, Owkin\u2019s head of product, described the platform as \u201cmodular by design.\u201d Architecturally, it runs on a two-track model strategy.<\/p>\n
It runs on a two-track model strategy. The first track uses frontier models from vendors such as Anthropic and OpenAI as the reasoning engines. Because those models are proprietary, Owkin can\u2019t touch their weights, so it improves everything around them instead: the tools, the instructions, and what B\u00e9al calls \u201crecipes that teach them how to accomplish a given task.\u201d That is in-context and tool learning rather than retraining the model.<\/p>\n
The second track uses open-weight models Owkin can modify directly. Its in-house example is OwkinZero, a smaller model the company fine-tunes with reinforcement learning on biological data and feeds back into the system. For that open-weight work, B\u00e9al said Owkin has leaned on the Qwen models for their strong ratio of performance to size, and is now investigating newer releases such as Kimi.<\/p>\n
Supporting both tracks is K Pro\u2019s multimodal patient-data network, drawn from partnerships with hundreds of academic centers, which B\u00e9al called the difference between real biological insight and, without it, \u201cLLM guesses.\u201d<\/p>\n
The expanded Sanofi is part of a broader pattern. In May, Owkin struck a structurally similar arrangement with AstraZeneca<\/a>, a multi-year K Pro license under which it would build agents, initially for competitive intelligence, inside AstraZeneca\u2019s systems.<\/p>\n","protected":false},"excerpt":{"rendered":"A 3D rendering of a biological cell from the company\u2019s homepage, where it animates to reveal layers of…\n","protected":false},"author":2,"featured_media":63835,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[179,7493,25,10118,1719,375,1941,36234,36235,3466,5813,23237,36236,31205],"class_list":["post-63834","post","type-post","status-publish","format-standard","has-post-thumbnail","category-agentic-ai","tag-agentic-ai","tag-agentic-artificial-intelligence","tag-artificial-intelligence","tag-biopharma","tag-biotechnology","tag-clinical-trials","tag-drug-discovery","tag-k-pro","tag-mcp-servers","tag-multimodal-data","tag-oncology","tag-owkin","tag-owkinzero","tag-sanofi"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/63834","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/comments?post=63834"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/63834\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media\/63835"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media?parent=63834"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/categories?post=63834"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/tags?post=63834"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"A](\"https:\/\/www.europesays.com\/ai\/wp-content\/uploads\/2026\/06\/owkin-300x195.png\")
<\/p>\n